We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

SIGMA ALDRICH CORP.

Sigma-Aldrich is a life science and high technology company that develops, manufactures, purchases, and distributes v... read more Featured Products: More products

Download Mobile App




Plasma Cytokine Responses Characterized in Melioidosis

By LabMedica International staff writers
Posted on 04 Dec 2019
Print article
Image: Colonies of Burkholderia pseudomallei on Ashdown`s agar after four days` incubation (Photo courtesy of Gavin Koh)
Image: Colonies of Burkholderia pseudomallei on Ashdown`s agar after four days` incubation (Photo courtesy of Gavin Koh)
Melioidosis, an infectious disease caused by the environmental saprophyte Burkholderia pseudomallei, is endemic across many areas of Southeast Asia, South Asia, Northern Australia and America. B. pseudomallei is a facultative intracellular bacterium, a characteristic that contributes to its pathogenesis and persistence in the host and that may modulate the cytokine response to infection.

Patients may present with a wide range of clinical manifestations including pneumonia, bacteremia, abscesses, and sepsis, frequently leading to multiorgan failure and eventually death. The immunological markers and pathways that identify patients at risk of death in melioidosis are not well understood. Several immune cells including macrophages, natural killer (NK) cells, NK T cells, and T cells respond to bacterial infection rapidly by generation of several potent cytokines.

Microbiologists and immunologists at the Mahidol University (Bangkok, Thailand) conducted a prospective longitudinal study in two hospitals in Northeast Thailand to enroll 161 melioidosis patients, 13 uninfected healthy controls, and 11 uninfected diabetic controls. Blood was obtained from all individuals at enrollment (day 0) and at days 5, 12, and 28 from surviving melioidosis patients. IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-23, and TNF-α were assayed in plasma. These were determined in human plasma samples using bead-based multiplex assays of Luminex technology (MILLIPLEX MAP kit: HSTCMAG-28K-12 plex, Millipore, Billerica, MA, USA). The association of each cytokine and its dynamics with 28-day mortality was determined.

The investigators reported that of melioidosis patients, 131/161 (81%) were bacteremic, and 68/161 (42%) died. On enrollment median levels of IFN-γ, IL-6, IL-8, IL-10, IL-23, and TNF-α were higher in melioidosis patients compared with uninfected healthy controls and all but IFN-γ were positively associated with 28-day mortality. IL-8 provided the best discrimination of mortality. Over time, non-survivors had increasing IL-6, IL-8, and IL-17A levels, in contrast to survivors. In joint modeling, temporal trajectories of IFN-γ, IL-6, IL-8, IL-10, and TNF-α predicted survival.

The authors concluded that in a severely ill cohort of melioidosis patients, specific pro- and anti-inflammatory and Th17 cytokines were associated with survival from melioidosis, at enrollment and over time. Persistent inflammation preceded death. These findings support further evaluation of these mediators as prognostic biomarkers and to guide targeted immunotherapeutic development for severe melioidosis. The study was published on November 7, 2019 in the journal Clinical Microbiology and Infection.

Related Links:
Mahidol University
Millipore


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chagas Disease Test
LIAISON Chagas
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.